A Real-World Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Patients Receiving Dupilumab Therapy, With Atopic Dermatitis Control Tool in Gulf Countries
Latest Information Update: 30 Nov 2023
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms AD-impaCT
- Sponsors Sanofi
- 23 Nov 2023 Status changed from active, no longer recruiting to completed.
- 16 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2022 Status changed from not yet recruiting to recruiting.